# Phase 4 lymphoma trials recruiting: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials in phase 4 for lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 lymphoma trials: 21 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07934537 | Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large... | Shanghai Tongji Hospital, Tongji University School of Medicine | Phase 4 | Recruiting | Large B-Cell Lymphoma (LBCL), Lymphoma, Large B-Cell, Diffuse | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934537) |
| November 2, 2026 | NCT07908888 | Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in... | The First Hospital of Jilin University | Phase 4 | Recruiting | Diffuse Large B-Cell Lymphoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908888) |
| August 12, 2026 | NCT07760610 | Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response | The First Hospital of Jilin University | Phase 4 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760610) |
| February 23, 2026 | NCT07426484 | Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy | Dana-Farber Cancer Institute | Phase 4 | Recruiting | Cutaneous Squamous Cell Carcinoma, Skin Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07426484) |
| January 21, 2026 | NCT07355699 | Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma | Beijing Tongren Hospital | Phase 4 | Recruiting | Marginal Zone Lymphoma(MZL) | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07355699) |
| December 8, 2025 | NCT07270835 | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma | The First Affiliated Hospital of Soochow University | Phase 4 | Recruiting | Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07270835) |
| December 4, 2025 | NCT07264894 | ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial | Zhengzhou University | Phase 4 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07264894) |
| September 11, 2025 | NCT07167862 | Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound | University of California, Irvine | Phase 4 | Recruiting | Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07167862) |
| June 11, 2025 | NCT07016165 | Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies | Gadjah Mada University | Phase 4 | Recruiting | Neutropenic Fever, Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Non Hodgkin Lymphoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07016165) |
| May 2, 2025 | NCT06956092 | Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma | Zhengzhou University | Phase 4 | Not yet recruiting | B Cell Lymphoma (BCL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06956092) |
| March 14, 2025 | NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or... | Eli Lilly and Company | Phase 4 | Recruiting | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06876662) |
| March 14, 2025 | NCT06876649 | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | Eli Lilly and Company | Phase 4 | Recruiting | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | 787 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06876649) |
| February 18, 2025 | NCT06831370 | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India | Takeda | Phase 4 | Recruiting | Hodgkin Lymphoma | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06831370) |
| October 30, 2024 | NCT06665737 | Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients | Department of Medical Services Ministry of Public Health of Thailand | Phase 4 | Not yet recruiting | Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN), Myelosuppression Adult | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06665737) |
| September 24, 2024 | NCT06609304 | Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma | Zhengzhou University | Phase 4 | Recruiting | Lymphoma, B-Cell | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06609304) |
| November 18, 2023 | NCT06134284 | Clinical Study of OR for Second-line Treatment of Refractory MZL | Sponsor not shown (see the record) | Phase 4 | Recruiting | OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06134284) |
| April 18, 2023 | NCT05814848 | A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma | Changhai Hospital | Phase 4 | Not yet recruiting | Relapsed or Refractory B-cell Lymphoma | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05814848) |
| April 10, 2023 | NCT05806580 | Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma | Ruijin Hospital | Phase 4 | Recruiting | Relapsed or Refractory B-cell Lymphoma | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05806580) |
| August 26, 2022 | NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 | Recruiting | Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma, Primary CNS Lymphoma, Diffuse Large B-cell... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05518383) |
| December 28, 2021 | NCT05170399 | Vaccine Responses in Patients With B Cell Malignancies | National Heart, Lung, and Blood Institute (NHLBI) | Phase 4 | Recruiting | Lymphoma | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05170399) |
| July 7, 2020 | NCT04460235 | Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients... | Poitiers University Hospital | Phase 4 | Recruiting | Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04460235) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Zhengzhou University | 3 |
| The First Hospital of Jilin University | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| Ruijin Hospital | 1 |
| Department of Medical Services Ministry of Public Health of Thailand | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Poitiers University Hospital | 1 |
| University of California, Irvine | 1 |
| Beijing Tongren Hospital | 1 |
| Gadjah Mada University | 1 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 1 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 1 |
| Dana-Farber Cancer Institute | 1 |
| Changhai Hospital | 1 |
| Shanghai Tongji Hospital, Tongji University School of Medicine | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 9 |
| United States | 5 |
| France | 3 |
| Australia | 2 |
| Italy | 2 |
| Japan | 2 |
| Poland | 2 |
| South Korea | 2 |
| United Kingdom | 2 |
| Thailand | 1 |
| Indonesia | 1 |
| India | 1 |
| Russia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sign makers in the United States](https://specstream.ai/data/businesses/sign-makers/united-states)
- [Plastics companies in the United States](https://specstream.ai/data/businesses/plastics-companies/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Importers in the United States](https://specstream.ai/data/businesses/importers/united-states)
- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [Deck builders in the United States](https://specstream.ai/data/businesses/deck-builders/united-states)
